MIF-Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
MIF-Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
批准号:
8666033
负责人:
EDMUND J MILLER
金额:
$41.28万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-06-01 至 2017-05-31
关键词:
AddressAnimal ModelBiological AvailabilityBiologyBloodBlood VesselsCardiopulmonaryCardiovascular DiseasesCell ProliferationCellsCessation of lifeChronicClinical ResearchClinical ServicesCoupledDataDevelopmentDiseaseDisease ProgressionEquilibriumExerciseGoalsHeart failureHigh PrevalenceHumanHypertensionHypothyroidismHypoxemiaHypoxiaImmigrationIn VitroIndividualInflammatoryInterventionKnockout MiceLigandsLungMediator of activation proteinMigration Inhibitory FactorMolecularMusMyocardial InfarctionObstructive Sleep ApneaOxygenPathogenesisPathway interactionsPatientsPhysiologicalPlasmaPlayPulmonary FibrosisPulmonary Heart DiseasePulmonary HypertensionReportingResearch PersonnelRoleSideSignal TransductionSignaling MoleculeStrokeSymptomsTestingTherapeuticThyroid HormonesThyroxineVascular remodelingVentricularWorkclinically relevantconstrictioncytokineeffective therapyexpectationextracellularinhibitor/antagonistinnovationmouse modelnon-genomicnovel therapeutic interventionoutcome forecastphenylpyruvate tautomerasepublic health relevancepulmonary arterial hypertensionreceptorsmall moleculestem
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Pulmonary Arterial Hypertension (PAH) is a chronic progressive disorder that leads to remodeling of blood vessels in the lung, low oxygen in the blood, right-sided heart failure and death. The poor prognosis and lack of effective PAH disease-modifying agents underscore the need for a better understanding of disease pathogenesis in order to identify new therapeutic approaches. This proposal addresses the molecular mechanisms involved in the development and progression of PAH. Specifically, we will examine - at both the physiological and the cellular level - the effects of a previously unrecognized, clinically relevant interaction between a proinflammatory cytokine [Macrophage Migration Inhibitory Factor (MIF)] and a thyroid hormone [Thyroxine (T4)] in PAH. We have identified MIF as a critical mediator in the development and progression of PAH and further, we have made the surprising discovery that T4 is a natural ligand for and inhibitor of MIF's inflammatory activity. We hypothesize that the dramatic increase in circulating MIF observed during the development of PAH alters the normal plasma MIF-free T4 ratio and underlies the high prevalence of hypothyroidism that has been reported in patients with pulmonary hypertension. The modified status of MIF and T4 in the plasma profoundly changes the interactions of these molecules with their respective cellular receptors leading to altered intracellular signaling and vascular cell proliferation. We outline a multi-faceted approach involving clinical studies, animal models and in vitro assessments. We will examine the MIF-T4 relationship in patients with PAH, both during disease progression and before/after a standardized exercise challenge. We will further examine the interrelationship between these molecules in both animal models of pulmonary vascular remodeling and at a cellular level to understand better the consequence of the interaction on intracellular signaling and cell replication. The long term goal of the project is to exploit the relationship between these molecules to develop new and more effective therapeutic approaches for the treatment this devastating disease. While this proposal focuses on the interactions of MIF and T4 in the pathogenesis of PAH, data achieved in the study will be directly relevant to other cardiopulmonary disease states in which MIF is increased including stroke, cardiovascular disease, myocardial infarction, pulmonary fibrosis and obstructive sleep apnea.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MIF-Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
-
批准号:8502955
-
项目类别:
-
资助金额:$40.1万
-
财政年份:2013
-
负责人:EDMUND J MILLER
-
依托单位:
MIF-Thyroxine Interactions in the Pathogenesis of Pulmonary Arterial Hypertension
-
批准号:9120922
-
项目类别:
-
资助金额:$42.13万
-
财政年份:2013
-
负责人:EDMUND J MILLER
-
依托单位:
The Lung as a Source of Inflammation in Sepsis
-
批准号:7204222
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:EDMUND J MILLER
-
依托单位:
The Lung as a Source of Inflammation in Sepsis
-
批准号:7371136
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:EDMUND J MILLER
-
依托单位:
The Lung as a Source of Inflammation in Sepsis
-
批准号:7093259
-
项目类别:
-
资助金额:$41.38万
-
财政年份:2006
-
负责人:EDMUND J MILLER
-
依托单位:
The Lung as a Source of Inflammation in Sepsis
-
批准号:7577416
-
项目类别:
-
资助金额:$40.18万
-
财政年份:2006
-
负责人:EDMUND J MILLER
-
依托单位:
Mechanisms Regulating Human Neutrophil Apoptosis
-
批准号:6782489
-
项目类别:
-
资助金额:$31.59万
-
财政年份:2001
-
负责人:EDMUND J MILLER
-
依托单位:
STAPHYLOCOCCAL TOXINS AND IL8 AND ARDS
-
批准号:6125788
-
项目类别:
-
资助金额:$9.89万
-
财政年份:1996
-
负责人:EDMUND J MILLER
-
依托单位:
STAPHYLOCOCCAL TOXINS AND IL8 AND ARDS
-
批准号:2609361
-
项目类别:
-
资助金额:$9.23万
-
财政年份:1996
-
负责人:EDMUND J MILLER
-
依托单位:
STAPHYLOCOCCAL TOXINS AND IL8 AND ARDS
-
批准号:2029704
-
项目类别:
-
资助金额:$5.86万
-
财政年份:1996
-
负责人:EDMUND J MILLER
-
依托单位:
STAPHYLOCOCCAL TOXINS AND IL8 AND ARDS
-
批准号:6573073
-
项目类别:
-
资助金额:$10.6万
-
财政年份:1996
-
负责人:EDMUND J MILLER
-
依托单位:
STAPHYLOCOCCAL TOXINS AND IL8 AND ARDS
-
批准号:2839026
-
项目类别:
-
资助金额:$9.72万
-
财政年份:1996
-
负责人:EDMUND J MILLER
-
依托单位:
海外基金